Latest News

Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program In...

Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integra

Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election ...

Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Ea

Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalid...

Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide

Teva to Present at the Barclays Global Healthcare Conference

Teva to Present at the Barclays Global Healthcare Conference

Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Se...

Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior

Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026

Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026

Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes

Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes

Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of All...

Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy,

Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Im...

Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact

Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-D...

Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily

Teva Reaches Agreement With Florida to Settle the State’s Price Fixing Claims

Teva Reaches Agreement With Florida to Settle the State’s Price Fixing Claims

Teva Reports Fourth Quarter and Full Year 2022 Financial Results

Teva Reports Fourth Quarter and Full Year 2022 Financial Results

Teva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)

Teva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023...

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023 Fina

Teva Announces Nationwide Opioids Settlement to Move Forward After Receiving Broad Support from Stat...

Teva Announces Nationwide Opioids Settlement to Move Forward After Receiving Broad Support from States